[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smoking-cessation-intervention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smoking-cessation-intervention":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,63,116,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":4},"100638763","smoking-cessation-with-wearables-to-improve-general-oral-health-and-quality-of-life-100638763",false,"NCT07593742","Smoking Cessation With Wearables to Improve General, Oral Health and Quality of Life","Smoking Cessation Programme in Telerehabilitation Assisted by Telemonitoring With Non-Invasive Wearable Devices for the Improvement of Oral Health, General Health and Quality of Life","Wear-Smile","Inclusion Criteria:\n\n* Subjects who smoke ≥ 5 cigarettes per day (traditional or equivalent in nicotine content in non-combustible tobacco or liquid\u002Fvape), regardless of the severity of nicotine dependence\n* Subjects ≥ 18 years of age\n* Ability and willingness to provide informed consent or presence of a legal representative who consents\n* Subjects in possession of home medical devices for measuring cardiopulmonary parameters (sphygmomanometer and pulse oximeter) (requirement applicable to participants assigned to the control group)\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Pregnant or breastfeeding women\n* Subjects with a remote or current history of using smoking cessation methods\n* Subjects with acute dependence on alcohol or other substances of abuse other than nicotine\n* Pathologies with advanced neurocognitive degeneration\n* Unstable psychiatric conditions (subjects with active suicidal ideation, hospitalization for psychiatric reasons and\u002For changes in psychiatric medication for less than 3 months)\n* Inability or refusal to sign informed consent\n* Inability to access the integrated telemedicine platform and\u002For wearable remote monitoring devices (requirement applicable to participants assigned to the experimental group)","ALL","18 Years",{"count":20,"type":21},102,"ESTIMATED","INTERVENTIONAL",[24],"NA","Tobacco smoking remains one of the leading preventable causes of disease, disability, and premature death worldwide. According to the World Health Organization, tobacco use is responsible for more than eight million deaths each year globally, including deaths caused by direct smoking and exposure to secondhand smoke. Smoking is a major risk factor for a wide range of chronic diseases, including cardiovascular diseases, chronic respiratory diseases, several types of cancer, and numerous oral health conditions. In addition to systemic effects, tobacco use is strongly associated with oral potentially malignant disorders and oral squamous cell carcinoma, representing a significant burden for public health systems.\n\nDespite the well-documented health risks, smoking cessation remains difficult for many individuals due to the addictive properties of nicotine and the complex behavioral and psychological components associated with tobacco dependence. Multimodal smoking cessation programs that combine behavioral counseling, psychological support, and continuous monitoring have been shown to increase the likelihood of successful cessation. However, access to these programs may be limited by logistical barriers, including geographic distance, time constraints, and limited availability of specialized services.\n\nIn recent years, telemedicine and digital health technologies have emerged as promising tools to support healthcare delivery and improve access to treatment programs. Telemedicine platforms allow remote interaction between patients and healthcare professionals, facilitating communication, follow-up, and monitoring of patients over time. Additionally, wearable devices and remote monitoring systems enable the collection of physiological and behavioral data outside traditional clinical settings, providing clinicians with valuable information to support personalized interventions.\n\nThe aim of this study is to evaluate the effectiveness and feasibility of a smoking cessation program delivered through a telerehabilitation model supported by an integrated telemedicine platform and wearable remote monitoring devices. The program is designed to support individuals who smoke tobacco products, including both combustible tobacco and alternative nicotine-containing products, by providing behavioral and psychological interventions combined with continuous remote monitoring.\n\nParticipants enrolled in the study will be assigned to one of two groups. The intervention group will participate in a telerehabilitation program delivered through a dedicated telemedicine platform. This program will include structured behavioral and psychological treatment sessions aimed at supporting smoking cessation, along with remote monitoring through non-invasive wearable devices that allow healthcare professionals to track selected physiological parameters and patient engagement during the treatment process.\n\nThe control group will receive the same multimodal behavioral and psychological treatment program but delivered through conventional rehabilitation methods without the use of telemedicine technologies or wearable monitoring devices.\n\nBy comparing these two approaches, the study aims to explore whether the integration of telemedicine and wearable technologies into smoking cessation programs may improve patient engagement, facilitate monitoring, and potentially enhance the effectiveness of behavioral interventions aimed at reducing tobacco use. The findings of this study may contribute to the development of innovative digital health strategies for smoking cessation and provide evidence to support the integration of telemedicine into addiction treatment and preventive healthcare programs.",[27,28,29,30,31,32,33,34,35],"Smoking ( Cigarette)","Smoking (Tobacco) Addiction","Smoking Behaviors","Smoking Cessation","Smoking Dependence","Smoking Addiction","Smoking Cessation Intervention","Smoking E-cigarette","Smoking Abstinence",[37,38,39,40,41,42,43,44,45,46,47,48,49,50],"Smoking","Smoking cessation","Smoking addiction","Tobacco","Wearable device","Telerehabilitation","Oral Health","Periodontal Health","General Health","Quality of life","Periodontal disease","E-cigarette","Heat not burn tobacco","Smoking abstinence","NOT_YET_RECRUITING","2026-05-11",{"date":54,"type":55},"2026-05-18","ACTUAL",{"date":57,"type":21},"2026-06-01",{"date":59,"type":21},"2027-11-01",{"name":61,"class":62},"University of Salerno","OTHER",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100580432","implementation-of-tobacco-cessation-programming-at-community-behavioral-health-sites-100580432","NCT06837220","Implementation of Tobacco Cessation Programming at Community Behavioral Health Sites","Enhancing the Implementation of Tobacco Treatment: A Community-responsive Approach","Inclusion Criteria:\n\n* Identify as someone who currently smokes combustible cigarettes (at least 1 cigarette per day) on each day for the past month\n* Report interest in quitting cigarettes (at least 6\u002F10 scale in interest of quitting)\n* Age 18 or older, ability to understand the English language, willing and able to provide informed consent\n* Stable residence and contact information throughout the follow up period\n\nExclusion Criteria:\n\n* Non-daily or intermittent cigarette use\n* No interest in quitting smoking\n* Unstable residence\u002Fnot staying in Chicago for duration of study period\n* Current untreated severe substance use disorder (with the exception of tobacco use) or past-year serious untreated psychiatric illness (e.g. schizophrenia, bipolar disorder, obsessive compulsive disorder, unspecified psychosis, past-year suicide attempt)","26 Years",{"count":72,"type":21},24,[24],"The goal of this study is to: partner with Respiratory Health Association and determine barriers and unmet smoking cessation treatment needs from leaders in behavioral health organizations, treatment programs and adults who smoke (AWS) in Chicago. This will be accomplished by establishing a community advisory board (CAB) and pilot testing a community-informed smoking cessation treatment within a community behavioral health organization to determine its feasibility after addressing implementation issues.",[76,30,33],"Nicotine Use Disorder",[78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104],"smoking","smoking cessation","nicotine","nicotine use disorder","quitting smoking","quitting nicotine","respiratory health","telehealth","virtual","tobacco","tobacco treatment","community","behavioral health","chicago","group therapy","disparities","adults who smoke","cigarettes","tobacco cessation","cessation","abstinence","substance use","substance abuse","addiction","counseling","health counseling","health communication","RECRUITING","2026-04-09",{"date":108,"type":55},"2026-04-14",{"date":110,"type":21},"2026-05",{"date":112,"type":21},"2026-11",{"name":114,"class":62},"University of Chicago",1,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":115},"100599153","oklahoma-study-of-native-american-pain-risk-iv-smoking-cessation-and-pain-100599153","NCT07080788","Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain","Can Smoking Cessation Improve Physiological Markers of Chronic Pain Risk in Native American Smokers?: A Pilot Feasibility Study","OK-SNAPIV","Inclusion Criteria:\n\n* Self-identify as Native American\u002FAmerican Indian\n* Currently daily smoker\n* Own a smartphone with a data plan\n* Ability to speak and read English\n\nExclusion Criteria:\n\n* \\>18 years of age\n* Currently pregnant\n* Self-reported history of heart disease or heart attack\n* Angina, arrhythmias, hypertension, heart disease\n* Current chronic pain\n* Pepper allergy\n* Inability to speak English\n* Current psychosis (assessed by Psychosis Screening Questionnaire)\n* Serious cognitive impairment (assessed by \\\u003C20 score on the Montreal Cognitive Assessment \\[MoCA\\])",true,{"count":126,"type":21},150,[24],"The goal of this pilot study is to assess whether 4-weeks of verified smoking abstinence following financial incentive treatment for smoking cessation improves physiological markers of chronic pain risk in adult Native American smokers.\n\nThe main aims to answer are:\n\n1. Determine study feasibility.\n2. Obtain effect sizes for changes in pain amplification and pain inhibition in abstinent vs non-abstinent Native Americans.\n3. Obtain effect sizes for variables in the conceptual model of the Native American smoking-pain relationship.",[33,130,28],"Pain",[38,132],"Quantitative sensory testing","2026-02-26",{"date":135,"type":55},"2026-03-02",{"date":137,"type":55},"2025-09-01",{"date":139,"type":21},"2028-06",{"name":141,"class":62},"University of Oklahoma",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":154,"conditions":155,"keywords":160,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":115},"100552307","unraveling-the-genetic-basis-of-nicotine-addiction-for-novel-therapeutic-strategies-100552307","NCT06471387","Unraveling the Genetic Basis of Nicotine Addiction for Novel Therapeutic Strategies","Exploring the Genetic and Molecular Underpinning of Nicotine Addiction for the Development of New Therapeutic Strategies","NicoGen","Inclusion Criteria:\n\n* Adults aged 18-60 years old\n* Current daily cigarette smoker\n* Able to understand study procedures and provide informed consent\n* For females, non-pregnant and non-lactating\n\nExclusion Criteria:\n\n* Presence of significant uncontrolled medical conditions (e.g. cardiovascular disease, respiratory disorders, cancer) that could affect smoking behaviors or study participation\n* Presence of major uncontrolled psychiatric disorders (e.g. schizophrenia, bipolar disorder, severe depression)\n* Current substance use disorder (except nicotine dependence)\n* Taking medications that could significantly interfere with study objectives (e.g. medications for smoking cessation)\n* Significant cognitive impairment that precludes ability to complete study procedures","60 Years",{"count":152,"type":21},200,"OBSERVATIONAL","This case-control study aims to investigate the genetic and molecular bases of nicotine addiction to identify potential therapeutic targets. The project will involve drug repurposing using Mendelian Randomization, a smoking cessation intervention, and the analysis of methylation status in participants undergoing nicotine withdrawal.",[30,33,156,157,158,159],"Nicotine Addiction","Epigenetics","Molecular Biology","Genetic Epidemiology",[156,30,161,162,159,163,164],"Mendelian Randomization","Methylation","Drug Repurposing","Epigenetic Biomarkers","2024-06-23",{"date":167,"type":55},"2024-06-25",{"date":169,"type":55},"2023-11-01",{"date":171,"type":21},"2025-10-31",{"name":173,"class":62},"University of Cyprus"]